Pharma & Healthcare
Global Bacterial Vaccines for Humans Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 18, 25
- ID: 607060
- Pages: 163
- Figures: 168
- Views: 1
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Bacterial Vaccines for Humans market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Merck
Sanofi
GSK
Mitsubishi Tanabe Pharma
Pfizer
Bayer
Emergent BioSolutions
Walvax
Chengdu Kanghua Biological Products Co., Ltd.
Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
Beijing Institute of Biological Products Co., Ltd.
CanSino Biological Co., Ltd.
Hualan Biological Vaccine Co., Ltd.
Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
Segment by Type
Meningococcal Vaccine
Hib Vaccine
BCG Vaccine
Typhoid Vaccine
Anthrax Vaccine
Segment by Application
Hospital
Clinic
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Bacterial Vaccines for Humans study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Bacterial Vaccines for Humans market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Merck
Sanofi
GSK
Mitsubishi Tanabe Pharma
Pfizer
Bayer
Emergent BioSolutions
Walvax
Chengdu Kanghua Biological Products Co., Ltd.
Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
Beijing Institute of Biological Products Co., Ltd.
CanSino Biological Co., Ltd.
Hualan Biological Vaccine Co., Ltd.
Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
Segment by Type
Meningococcal Vaccine
Hib Vaccine
BCG Vaccine
Typhoid Vaccine
Anthrax Vaccine
Segment by Application
Hospital
Clinic
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Bacterial Vaccines for Humans study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Bacterial Vaccines for Humans: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Bacterial Vaccines for Humans Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Meningococcal Vaccine
1.2.3 Hib Vaccine
1.2.4 BCG Vaccine
1.2.5 Typhoid Vaccine
1.2.6 Anthrax Vaccine
1.3 Market Segmentation by Application
1.3.1 Global Bacterial Vaccines for Humans Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Bacterial Vaccines for Humans Revenue Estimates and Forecasts 2020-2031
2.2 Global Bacterial Vaccines for Humans Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Bacterial Vaccines for Humans Sales Estimates and Forecasts 2020-2031
2.4 Global Bacterial Vaccines for Humans Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Bacterial Vaccines for Humans Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Bacterial Vaccines for Humans Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Meningococcal Vaccine Market Size by Manufacturers
3.5.2 Hib Vaccine Market Size by Manufacturers
3.5.3 BCG Vaccine Market Size by Manufacturers
3.5.4 Typhoid Vaccine Market Size by Manufacturers
3.5.5 Anthrax Vaccine Market Size by Manufacturers
3.6 Global Bacterial Vaccines for Humans Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Bacterial Vaccines for Humans Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Bacterial Vaccines for Humans Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Bacterial Vaccines for Humans Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Bacterial Vaccines for Humans Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Bacterial Vaccines for Humans Sales and Revenue by Type (2020-2031)
6.4 North America Bacterial Vaccines for Humans Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Bacterial Vaccines for Humans Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Bacterial Vaccines for Humans Sales and Revenue by Type (2020-2031)
7.4 Europe Bacterial Vaccines for Humans Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Bacterial Vaccines for Humans Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Bacterial Vaccines for Humans Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Bacterial Vaccines for Humans Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Bacterial Vaccines for Humans Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Bacterial Vaccines for Humans Sales and Revenue by Type (2020-2031)
9.4 Central and South America Bacterial Vaccines for Humans Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Bacterial Vaccines for Humans Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Bacterial Vaccines for Humans Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Bacterial Vaccines for Humans Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Bacterial Vaccines for Humans Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Business Overview
11.1.3 Merck Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.1.4 Merck Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Merck Bacterial Vaccines for Humans Sales by Product in 2024
11.1.6 Merck Bacterial Vaccines for Humans Sales by Application in 2024
11.1.7 Merck Bacterial Vaccines for Humans Sales by Geographic Area in 2024
11.1.8 Merck Bacterial Vaccines for Humans SWOT Analysis
11.1.9 Merck Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.2.4 Sanofi Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Bacterial Vaccines for Humans Sales by Product in 2024
11.2.6 Sanofi Bacterial Vaccines for Humans Sales by Application in 2024
11.2.7 Sanofi Bacterial Vaccines for Humans Sales by Geographic Area in 2024
11.2.8 Sanofi Bacterial Vaccines for Humans SWOT Analysis
11.2.9 Sanofi Recent Developments
11.3 GSK
11.3.1 GSK Corporation Information
11.3.2 GSK Business Overview
11.3.3 GSK Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.3.4 GSK Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 GSK Bacterial Vaccines for Humans Sales by Product in 2024
11.3.6 GSK Bacterial Vaccines for Humans Sales by Application in 2024
11.3.7 GSK Bacterial Vaccines for Humans Sales by Geographic Area in 2024
11.3.8 GSK Bacterial Vaccines for Humans SWOT Analysis
11.3.9 GSK Recent Developments
11.4 Mitsubishi Tanabe Pharma
11.4.1 Mitsubishi Tanabe Pharma Corporation Information
11.4.2 Mitsubishi Tanabe Pharma Business Overview
11.4.3 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.4.4 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Sales by Product in 2024
11.4.6 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Sales by Application in 2024
11.4.7 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Sales by Geographic Area in 2024
11.4.8 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans SWOT Analysis
11.4.9 Mitsubishi Tanabe Pharma Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.5.4 Pfizer Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Pfizer Bacterial Vaccines for Humans Sales by Product in 2024
11.5.6 Pfizer Bacterial Vaccines for Humans Sales by Application in 2024
11.5.7 Pfizer Bacterial Vaccines for Humans Sales by Geographic Area in 2024
11.5.8 Pfizer Bacterial Vaccines for Humans SWOT Analysis
11.5.9 Pfizer Recent Developments
11.6 Bayer
11.6.1 Bayer Corporation Information
11.6.2 Bayer Business Overview
11.6.3 Bayer Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.6.4 Bayer Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Bayer Recent Developments
11.7 Emergent BioSolutions
11.7.1 Emergent BioSolutions Corporation Information
11.7.2 Emergent BioSolutions Business Overview
11.7.3 Emergent BioSolutions Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.7.4 Emergent BioSolutions Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Emergent BioSolutions Recent Developments
11.8 Walvax
11.8.1 Walvax Corporation Information
11.8.2 Walvax Business Overview
11.8.3 Walvax Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.8.4 Walvax Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Walvax Recent Developments
11.9 Chengdu Kanghua Biological Products Co., Ltd.
11.9.1 Chengdu Kanghua Biological Products Co., Ltd. Corporation Information
11.9.2 Chengdu Kanghua Biological Products Co., Ltd. Business Overview
11.9.3 Chengdu Kanghua Biological Products Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.9.4 Chengdu Kanghua Biological Products Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Developments
11.10 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
11.10.1 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Corporation Information
11.10.2 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Business Overview
11.10.3 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.10.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Recent Developments
11.11 Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
11.11.1 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Corporation Information
11.11.2 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Business Overview
11.11.3 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.11.4 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Recent Developments
11.12 Beijing Institute of Biological Products Co., Ltd.
11.12.1 Beijing Institute of Biological Products Co., Ltd. Corporation Information
11.12.2 Beijing Institute of Biological Products Co., Ltd. Business Overview
11.12.3 Beijing Institute of Biological Products Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.12.4 Beijing Institute of Biological Products Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Beijing Institute of Biological Products Co., Ltd. Recent Developments
11.13 CanSino Biological Co., Ltd.
11.13.1 CanSino Biological Co., Ltd. Corporation Information
11.13.2 CanSino Biological Co., Ltd. Business Overview
11.13.3 CanSino Biological Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.13.4 CanSino Biological Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 CanSino Biological Co., Ltd. Recent Developments
11.14 Hualan Biological Vaccine Co., Ltd.
11.14.1 Hualan Biological Vaccine Co., Ltd. Corporation Information
11.14.2 Hualan Biological Vaccine Co., Ltd. Business Overview
11.14.3 Hualan Biological Vaccine Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.14.4 Hualan Biological Vaccine Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Hualan Biological Vaccine Co., Ltd. Recent Developments
11.15 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
11.15.1 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Corporation Information
11.15.2 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Business Overview
11.15.3 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.15.4 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Bacterial Vaccines for Humans Industry Chain
12.2 Bacterial Vaccines for Humans Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Bacterial Vaccines for Humans Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Bacterial Vaccines for Humans Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Bacterial Vaccines for Humans Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Bacterial Vaccines for Humans Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Bacterial Vaccines for Humans: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Bacterial Vaccines for Humans Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Meningococcal Vaccine
1.2.3 Hib Vaccine
1.2.4 BCG Vaccine
1.2.5 Typhoid Vaccine
1.2.6 Anthrax Vaccine
1.3 Market Segmentation by Application
1.3.1 Global Bacterial Vaccines for Humans Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Bacterial Vaccines for Humans Revenue Estimates and Forecasts 2020-2031
2.2 Global Bacterial Vaccines for Humans Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Bacterial Vaccines for Humans Sales Estimates and Forecasts 2020-2031
2.4 Global Bacterial Vaccines for Humans Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Bacterial Vaccines for Humans Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Bacterial Vaccines for Humans Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Meningococcal Vaccine Market Size by Manufacturers
3.5.2 Hib Vaccine Market Size by Manufacturers
3.5.3 BCG Vaccine Market Size by Manufacturers
3.5.4 Typhoid Vaccine Market Size by Manufacturers
3.5.5 Anthrax Vaccine Market Size by Manufacturers
3.6 Global Bacterial Vaccines for Humans Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Bacterial Vaccines for Humans Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Bacterial Vaccines for Humans Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Bacterial Vaccines for Humans Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Bacterial Vaccines for Humans Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Bacterial Vaccines for Humans Sales and Revenue by Type (2020-2031)
6.4 North America Bacterial Vaccines for Humans Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Bacterial Vaccines for Humans Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Bacterial Vaccines for Humans Sales and Revenue by Type (2020-2031)
7.4 Europe Bacterial Vaccines for Humans Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Bacterial Vaccines for Humans Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Bacterial Vaccines for Humans Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Bacterial Vaccines for Humans Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Bacterial Vaccines for Humans Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Bacterial Vaccines for Humans Sales and Revenue by Type (2020-2031)
9.4 Central and South America Bacterial Vaccines for Humans Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Bacterial Vaccines for Humans Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Bacterial Vaccines for Humans Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Bacterial Vaccines for Humans Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Bacterial Vaccines for Humans Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Business Overview
11.1.3 Merck Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.1.4 Merck Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Merck Bacterial Vaccines for Humans Sales by Product in 2024
11.1.6 Merck Bacterial Vaccines for Humans Sales by Application in 2024
11.1.7 Merck Bacterial Vaccines for Humans Sales by Geographic Area in 2024
11.1.8 Merck Bacterial Vaccines for Humans SWOT Analysis
11.1.9 Merck Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.2.4 Sanofi Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Bacterial Vaccines for Humans Sales by Product in 2024
11.2.6 Sanofi Bacterial Vaccines for Humans Sales by Application in 2024
11.2.7 Sanofi Bacterial Vaccines for Humans Sales by Geographic Area in 2024
11.2.8 Sanofi Bacterial Vaccines for Humans SWOT Analysis
11.2.9 Sanofi Recent Developments
11.3 GSK
11.3.1 GSK Corporation Information
11.3.2 GSK Business Overview
11.3.3 GSK Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.3.4 GSK Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 GSK Bacterial Vaccines for Humans Sales by Product in 2024
11.3.6 GSK Bacterial Vaccines for Humans Sales by Application in 2024
11.3.7 GSK Bacterial Vaccines for Humans Sales by Geographic Area in 2024
11.3.8 GSK Bacterial Vaccines for Humans SWOT Analysis
11.3.9 GSK Recent Developments
11.4 Mitsubishi Tanabe Pharma
11.4.1 Mitsubishi Tanabe Pharma Corporation Information
11.4.2 Mitsubishi Tanabe Pharma Business Overview
11.4.3 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.4.4 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Sales by Product in 2024
11.4.6 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Sales by Application in 2024
11.4.7 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Sales by Geographic Area in 2024
11.4.8 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans SWOT Analysis
11.4.9 Mitsubishi Tanabe Pharma Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.5.4 Pfizer Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Pfizer Bacterial Vaccines for Humans Sales by Product in 2024
11.5.6 Pfizer Bacterial Vaccines for Humans Sales by Application in 2024
11.5.7 Pfizer Bacterial Vaccines for Humans Sales by Geographic Area in 2024
11.5.8 Pfizer Bacterial Vaccines for Humans SWOT Analysis
11.5.9 Pfizer Recent Developments
11.6 Bayer
11.6.1 Bayer Corporation Information
11.6.2 Bayer Business Overview
11.6.3 Bayer Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.6.4 Bayer Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Bayer Recent Developments
11.7 Emergent BioSolutions
11.7.1 Emergent BioSolutions Corporation Information
11.7.2 Emergent BioSolutions Business Overview
11.7.3 Emergent BioSolutions Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.7.4 Emergent BioSolutions Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Emergent BioSolutions Recent Developments
11.8 Walvax
11.8.1 Walvax Corporation Information
11.8.2 Walvax Business Overview
11.8.3 Walvax Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.8.4 Walvax Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Walvax Recent Developments
11.9 Chengdu Kanghua Biological Products Co., Ltd.
11.9.1 Chengdu Kanghua Biological Products Co., Ltd. Corporation Information
11.9.2 Chengdu Kanghua Biological Products Co., Ltd. Business Overview
11.9.3 Chengdu Kanghua Biological Products Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.9.4 Chengdu Kanghua Biological Products Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Developments
11.10 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
11.10.1 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Corporation Information
11.10.2 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Business Overview
11.10.3 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.10.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Recent Developments
11.11 Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
11.11.1 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Corporation Information
11.11.2 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Business Overview
11.11.3 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.11.4 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Recent Developments
11.12 Beijing Institute of Biological Products Co., Ltd.
11.12.1 Beijing Institute of Biological Products Co., Ltd. Corporation Information
11.12.2 Beijing Institute of Biological Products Co., Ltd. Business Overview
11.12.3 Beijing Institute of Biological Products Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.12.4 Beijing Institute of Biological Products Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Beijing Institute of Biological Products Co., Ltd. Recent Developments
11.13 CanSino Biological Co., Ltd.
11.13.1 CanSino Biological Co., Ltd. Corporation Information
11.13.2 CanSino Biological Co., Ltd. Business Overview
11.13.3 CanSino Biological Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.13.4 CanSino Biological Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 CanSino Biological Co., Ltd. Recent Developments
11.14 Hualan Biological Vaccine Co., Ltd.
11.14.1 Hualan Biological Vaccine Co., Ltd. Corporation Information
11.14.2 Hualan Biological Vaccine Co., Ltd. Business Overview
11.14.3 Hualan Biological Vaccine Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.14.4 Hualan Biological Vaccine Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Hualan Biological Vaccine Co., Ltd. Recent Developments
11.15 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
11.15.1 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Corporation Information
11.15.2 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Business Overview
11.15.3 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Bacterial Vaccines for Humans Product Models, Descriptions and Specifications
11.15.4 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Bacterial Vaccines for Humans Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Bacterial Vaccines for Humans Industry Chain
12.2 Bacterial Vaccines for Humans Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Bacterial Vaccines for Humans Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Bacterial Vaccines for Humans Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Bacterial Vaccines for Humans Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Bacterial Vaccines for Humans Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Bacterial Vaccines for Humans Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Bacterial Vaccines for Humans Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Bacterial Vaccines for Humans Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Bacterial Vaccines for Humans Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Bacterial Vaccines for Humans Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Bacterial Vaccines for Humans Sales by Region (2020-2025) & (K Units)
Table 8. Global Bacterial Vaccines for Humans Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Bacterial Vaccines for Humans Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Bacterial Vaccines for Humans Sales Share by Manufacturers (2020-2025)
Table 12. Global Bacterial Vaccines for Humans Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Bacterial Vaccines for Humans Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Bacterial Vaccines for Humans by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bacterial Vaccines for Humans as of 2024)
Table 16. Global Bacterial Vaccines for Humans Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Bacterial Vaccines for Humans Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Bacterial Vaccines for Humans Manufacturing Base and Headquarters
Table 19. Global Bacterial Vaccines for Humans Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Bacterial Vaccines for Humans Sales by Type (2020-2025) & (K Units)
Table 23. Global Bacterial Vaccines for Humans Sales by Type (2026-2031) & (K Units)
Table 24. Global Bacterial Vaccines for Humans Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Bacterial Vaccines for Humans Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Bacterial Vaccines for Humans ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Bacterial Vaccines for Humans Sales by Application (2020-2025) & (K Units)
Table 29. Global Bacterial Vaccines for Humans Sales by Application (2026-2031) & (K Units)
Table 30. Bacterial Vaccines for Humans High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Bacterial Vaccines for Humans Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Bacterial Vaccines for Humans Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Bacterial Vaccines for Humans ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Bacterial Vaccines for Humans Growth Accelerators and Market Barriers
Table 37. North America Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Bacterial Vaccines for Humans Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Bacterial Vaccines for Humans Growth Accelerators and Market Barriers
Table 40. Europe Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Bacterial Vaccines for Humans Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Bacterial Vaccines for Humans Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Bacterial Vaccines for Humans Growth Accelerators and Market Barriers
Table 45. Southeast Asia Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Bacterial Vaccines for Humans Investment Opportunities and Key Challenges
Table 47. Central and South America Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Bacterial Vaccines for Humans Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Merck Corporation Information
Table 51. Merck Description and Major Businesses
Table 52. Merck Product Models, Descriptions and Specifications
Table 53. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Merck Sales Value Proportion by Product in 2024
Table 55. Merck Sales Value Proportion by Application in 2024
Table 56. Merck Sales Value Proportion by Geographic Area in 2024
Table 57. Merck Bacterial Vaccines for Humans SWOT Analysis
Table 58. Merck Recent Developments
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Major Businesses
Table 61. Sanofi Product Models, Descriptions and Specifications
Table 62. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Sanofi Sales Value Proportion by Product in 2024
Table 64. Sanofi Sales Value Proportion by Application in 2024
Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 66. Sanofi Bacterial Vaccines for Humans SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. GSK Corporation Information
Table 69. GSK Description and Major Businesses
Table 70. GSK Product Models, Descriptions and Specifications
Table 71. GSK Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. GSK Sales Value Proportion by Product in 2024
Table 73. GSK Sales Value Proportion by Application in 2024
Table 74. GSK Sales Value Proportion by Geographic Area in 2024
Table 75. GSK Bacterial Vaccines for Humans SWOT Analysis
Table 76. GSK Recent Developments
Table 77. Mitsubishi Tanabe Pharma Corporation Information
Table 78. Mitsubishi Tanabe Pharma Description and Major Businesses
Table 79. Mitsubishi Tanabe Pharma Product Models, Descriptions and Specifications
Table 80. Mitsubishi Tanabe Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Mitsubishi Tanabe Pharma Sales Value Proportion by Product in 2024
Table 82. Mitsubishi Tanabe Pharma Sales Value Proportion by Application in 2024
Table 83. Mitsubishi Tanabe Pharma Sales Value Proportion by Geographic Area in 2024
Table 84. Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans SWOT Analysis
Table 85. Mitsubishi Tanabe Pharma Recent Developments
Table 86. Pfizer Corporation Information
Table 87. Pfizer Description and Major Businesses
Table 88. Pfizer Product Models, Descriptions and Specifications
Table 89. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Pfizer Sales Value Proportion by Product in 2024
Table 91. Pfizer Sales Value Proportion by Application in 2024
Table 92. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 93. Pfizer Bacterial Vaccines for Humans SWOT Analysis
Table 94. Pfizer Recent Developments
Table 95. Bayer Corporation Information
Table 96. Bayer Description and Major Businesses
Table 97. Bayer Product Models, Descriptions and Specifications
Table 98. Bayer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Bayer Recent Developments
Table 100. Emergent BioSolutions Corporation Information
Table 101. Emergent BioSolutions Description and Major Businesses
Table 102. Emergent BioSolutions Product Models, Descriptions and Specifications
Table 103. Emergent BioSolutions Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Emergent BioSolutions Recent Developments
Table 105. Walvax Corporation Information
Table 106. Walvax Description and Major Businesses
Table 107. Walvax Product Models, Descriptions and Specifications
Table 108. Walvax Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Walvax Recent Developments
Table 110. Chengdu Kanghua Biological Products Co., Ltd. Corporation Information
Table 111. Chengdu Kanghua Biological Products Co., Ltd. Description and Major Businesses
Table 112. Chengdu Kanghua Biological Products Co., Ltd. Product Models, Descriptions and Specifications
Table 113. Chengdu Kanghua Biological Products Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Chengdu Kanghua Biological Products Co., Ltd. Recent Developments
Table 115. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Corporation Information
Table 116. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Description and Major Businesses
Table 117. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 118. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Recent Developments
Table 120. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Corporation Information
Table 121. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Description and Major Businesses
Table 122. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 123. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Recent Developments
Table 125. Beijing Institute of Biological Products Co., Ltd. Corporation Information
Table 126. Beijing Institute of Biological Products Co., Ltd. Description and Major Businesses
Table 127. Beijing Institute of Biological Products Co., Ltd. Product Models, Descriptions and Specifications
Table 128. Beijing Institute of Biological Products Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Beijing Institute of Biological Products Co., Ltd. Recent Developments
Table 130. CanSino Biological Co., Ltd. Corporation Information
Table 131. CanSino Biological Co., Ltd. Description and Major Businesses
Table 132. CanSino Biological Co., Ltd. Product Models, Descriptions and Specifications
Table 133. CanSino Biological Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. CanSino Biological Co., Ltd. Recent Developments
Table 135. Hualan Biological Vaccine Co., Ltd. Corporation Information
Table 136. Hualan Biological Vaccine Co., Ltd. Description and Major Businesses
Table 137. Hualan Biological Vaccine Co., Ltd. Product Models, Descriptions and Specifications
Table 138. Hualan Biological Vaccine Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Hualan Biological Vaccine Co., Ltd. Recent Developments
Table 140. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Corporation Information
Table 141. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Description and Major Businesses
Table 142. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Product Models, Descriptions and Specifications
Table 143. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Recent Developments
Table 145. Key Raw Materials Distribution
Table 146. Raw Materials Key Suppliers
Table 147. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 148. Milestones in Production Technology Evolution
Table 149. Distributors List
Table 150. Market Trends and Market Evolution
Table 151. Market Drivers and Opportunities
Table 152. Market Challenges, Risks, and Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Bacterial Vaccines for Humans Product Picture
Figure 2. Global Bacterial Vaccines for Humans Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Meningococcal Vaccine Product Picture
Figure 4. Hib Vaccine Product Picture
Figure 5. BCG Vaccine Product Picture
Figure 6. Typhoid Vaccine Product Picture
Figure 7. Anthrax Vaccine Product Picture
Figure 8. Global Bacterial Vaccines for Humans Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Bacterial Vaccines for Humans Report Years Considered
Figure 13. Global Bacterial Vaccines for Humans Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 15. Global Bacterial Vaccines for Humans Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Bacterial Vaccines for Humans Revenue Market Share by Region (2020-2031)
Figure 17. Global Bacterial Vaccines for Humans Sales (2020-2031) & (K Units)
Figure 18. Global Bacterial Vaccines for Humans Sales (CAGR) by Region (2020-2031) (K Units)
Figure 19. Global Bacterial Vaccines for Humans Sales Market Share by Region (2020-2031)
Figure 20. Top 5 and Top 10 Manufacturers Bacterial Vaccines for Humans Sales Volume Market Share in 2024
Figure 21. Global Bacterial Vaccines for Humans Revenue Market Share Ranking (2024)
Figure 22. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 23. Meningococcal Vaccine Revenue Market Share by Manufacturer in 2024
Figure 24. Hib Vaccine Revenue Market Share by Manufacturer in 2024
Figure 25. BCG Vaccine Revenue Market Share by Manufacturer in 2024
Figure 26. Typhoid Vaccine Revenue Market Share by Manufacturer in 2024
Figure 27. Anthrax Vaccine Revenue Market Share by Manufacturer in 2024
Figure 28. Global Bacterial Vaccines for Humans Sales Market Share by Type (2020-2031)
Figure 29. Global Bacterial Vaccines for Humans Revenue Market Share by Type (2020-2031)
Figure 30. Global Bacterial Vaccines for Humans Sales Market Share by Application (2020-2031)
Figure 31. Global Bacterial Vaccines for Humans Revenue Market Share by Application (2020-2031)
Figure 32. North America Bacterial Vaccines for Humans Sales YoY (2020-2031) & (K Units)
Figure 33. North America Bacterial Vaccines for Humans Revenue YoY (2020-2031) & (US$ Million)
Figure 34. North America Top 5 Manufacturers Bacterial Vaccines for Humans Sales Revenue (US$ Million) in 2024
Figure 35. North America Bacterial Vaccines for Humans Sales Volume (K Units) by Type (2020- 2031)
Figure 36. North America Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 37. North America Bacterial Vaccines for Humans Sales Volume (K Units) by Application (2020-2031)
Figure 38. North America Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Application (2020-2031)
Figure 39. US Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 40. Canada Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 41. Mexico Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 42. Europe Bacterial Vaccines for Humans Sales YoY (2020-2031) & (K Units)
Figure 43. Europe Bacterial Vaccines for Humans Revenue YoY (2020-2031) & (US$ Million)
Figure 44. Europe Top 5 Manufacturers Bacterial Vaccines for Humans Sales Revenue (US$ Million) in 2024
Figure 45. Europe Bacterial Vaccines for Humans Sales Volume (K Units) by Type (2020-2031)
Figure 46. Europe Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Type (2020-2031)
Figure 47. Europe Bacterial Vaccines for Humans Sales Volume (K Units) by Application (2020-2031)
Figure 48. Europe Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Application (2020-2031)
Figure 49. Germany Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 50. France Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 51. U.K. Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 52. Italy Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 53. Russia Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 54. Asia-Pacific Bacterial Vaccines for Humans Sales YoY (2020-2031) & (K Units)
Figure 55. Asia-Pacific Bacterial Vaccines for Humans Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Top 8 Manufacturers Bacterial Vaccines for Humans Sales Revenue (US$ Million) in 2024
Figure 57. Asia-Pacific Bacterial Vaccines for Humans Sales Volume (K Units) by Type (2020- 2031)
Figure 58. Asia-Pacific Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 59. Asia-Pacific Bacterial Vaccines for Humans Sales Volume (K Units) by Application (2020-2031)
Figure 60. Asia-Pacific Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Application (2020-2031)
Figure 61. Indonesia Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 62. Japan Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 63. South Korea Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 64. China Taiwan Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 65. India Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 66. Central and South America Bacterial Vaccines for Humans Sales YoY (2020-2031) & (K Units)
Figure 67. Central and South America Bacterial Vaccines for Humans Revenue YoY (2020-2031) & (US$ Million)
Figure 68. Central and South America Top 5 Manufacturers Bacterial Vaccines for Humans Sales Revenue (US$ Million) in 2024
Figure 69. Central and South America Bacterial Vaccines for Humans Sales Volume (K Units) by Type (2021-2031)
Figure 70. Central and South America Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Type (2020-2031)
Figure 71. Central and South America Bacterial Vaccines for Humans Sales Volume (K Units) by Application (2020-2031)
Figure 72. Central and South America Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Application (2020-2031)
Figure 73. Brazil Bacterial Vaccines for Humans Revenue (2020-2025) & (US$ Million)
Figure 74. Argentina Bacterial Vaccines for Humans Revenue (2020-2025) & (US$ Million)
Figure 75. Middle East, and Africa Bacterial Vaccines for Humans Sales YoY (2020-2031) & (K Units)
Figure 76. Middle East and Africa Bacterial Vaccines for Humans Revenue YoY (2020-2031) & (US$ Million)
Figure 77. Middle East and Africa Top 5 Manufacturers Bacterial Vaccines for Humans Sales Revenue (US$ Million) in 2024
Figure 78. Middle East and Africa Bacterial Vaccines for Humans Sales Volume (K Units) by Type (2021-2031)
Figure 79. South America Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Type (2020-2031)
Figure 80. Middle East and Africa Bacterial Vaccines for Humans Sales Volume (K Units) by Application (2020-2031)
Figure 81. Middle East and Africa Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Application (2020-2031)
Figure 82. GCC Countries Bacterial Vaccines for Humans Revenue (2020-2025) & (US$ Million)
Figure 83. Turkey Bacterial Vaccines for Humans Revenue (2020-2025) & (US$ Million)
Figure 84. Egypt Bacterial Vaccines for Humans Revenue (2020-2025) & (US$ Million)
Figure 85. South Africa Bacterial Vaccines for Humans Revenue (2020-2025) & (US$ Million)
Figure 86. Bacterial Vaccines for Humans Industry Chain Mapping
Figure 87. Regional Bacterial Vaccines for Humans Manufacturing Base Distribution (%)
Figure 88. Global Bacterial Vaccines for Humans Production Market Share by Region (2020-2031)
Figure 89. Bacterial Vaccines for Humans Production Process
Figure 90. Regional Bacterial Vaccines for Humans Production Cost Structure
Figure 91. Channels of Distribution (Direct Vs Distribution)
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed
Table 1. Global Bacterial Vaccines for Humans Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Bacterial Vaccines for Humans Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Bacterial Vaccines for Humans Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Bacterial Vaccines for Humans Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Bacterial Vaccines for Humans Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Bacterial Vaccines for Humans Sales by Region (2020-2025) & (K Units)
Table 8. Global Bacterial Vaccines for Humans Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Bacterial Vaccines for Humans Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Bacterial Vaccines for Humans Sales Share by Manufacturers (2020-2025)
Table 12. Global Bacterial Vaccines for Humans Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Bacterial Vaccines for Humans Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Bacterial Vaccines for Humans by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bacterial Vaccines for Humans as of 2024)
Table 16. Global Bacterial Vaccines for Humans Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Bacterial Vaccines for Humans Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Bacterial Vaccines for Humans Manufacturing Base and Headquarters
Table 19. Global Bacterial Vaccines for Humans Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Bacterial Vaccines for Humans Sales by Type (2020-2025) & (K Units)
Table 23. Global Bacterial Vaccines for Humans Sales by Type (2026-2031) & (K Units)
Table 24. Global Bacterial Vaccines for Humans Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Bacterial Vaccines for Humans Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Bacterial Vaccines for Humans ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Bacterial Vaccines for Humans Sales by Application (2020-2025) & (K Units)
Table 29. Global Bacterial Vaccines for Humans Sales by Application (2026-2031) & (K Units)
Table 30. Bacterial Vaccines for Humans High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Bacterial Vaccines for Humans Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Bacterial Vaccines for Humans Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Bacterial Vaccines for Humans ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Bacterial Vaccines for Humans Growth Accelerators and Market Barriers
Table 37. North America Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Bacterial Vaccines for Humans Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Bacterial Vaccines for Humans Growth Accelerators and Market Barriers
Table 40. Europe Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Bacterial Vaccines for Humans Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Bacterial Vaccines for Humans Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Bacterial Vaccines for Humans Growth Accelerators and Market Barriers
Table 45. Southeast Asia Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Bacterial Vaccines for Humans Investment Opportunities and Key Challenges
Table 47. Central and South America Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Bacterial Vaccines for Humans Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Bacterial Vaccines for Humans Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Merck Corporation Information
Table 51. Merck Description and Major Businesses
Table 52. Merck Product Models, Descriptions and Specifications
Table 53. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Merck Sales Value Proportion by Product in 2024
Table 55. Merck Sales Value Proportion by Application in 2024
Table 56. Merck Sales Value Proportion by Geographic Area in 2024
Table 57. Merck Bacterial Vaccines for Humans SWOT Analysis
Table 58. Merck Recent Developments
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Major Businesses
Table 61. Sanofi Product Models, Descriptions and Specifications
Table 62. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Sanofi Sales Value Proportion by Product in 2024
Table 64. Sanofi Sales Value Proportion by Application in 2024
Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 66. Sanofi Bacterial Vaccines for Humans SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. GSK Corporation Information
Table 69. GSK Description and Major Businesses
Table 70. GSK Product Models, Descriptions and Specifications
Table 71. GSK Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. GSK Sales Value Proportion by Product in 2024
Table 73. GSK Sales Value Proportion by Application in 2024
Table 74. GSK Sales Value Proportion by Geographic Area in 2024
Table 75. GSK Bacterial Vaccines for Humans SWOT Analysis
Table 76. GSK Recent Developments
Table 77. Mitsubishi Tanabe Pharma Corporation Information
Table 78. Mitsubishi Tanabe Pharma Description and Major Businesses
Table 79. Mitsubishi Tanabe Pharma Product Models, Descriptions and Specifications
Table 80. Mitsubishi Tanabe Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Mitsubishi Tanabe Pharma Sales Value Proportion by Product in 2024
Table 82. Mitsubishi Tanabe Pharma Sales Value Proportion by Application in 2024
Table 83. Mitsubishi Tanabe Pharma Sales Value Proportion by Geographic Area in 2024
Table 84. Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans SWOT Analysis
Table 85. Mitsubishi Tanabe Pharma Recent Developments
Table 86. Pfizer Corporation Information
Table 87. Pfizer Description and Major Businesses
Table 88. Pfizer Product Models, Descriptions and Specifications
Table 89. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Pfizer Sales Value Proportion by Product in 2024
Table 91. Pfizer Sales Value Proportion by Application in 2024
Table 92. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 93. Pfizer Bacterial Vaccines for Humans SWOT Analysis
Table 94. Pfizer Recent Developments
Table 95. Bayer Corporation Information
Table 96. Bayer Description and Major Businesses
Table 97. Bayer Product Models, Descriptions and Specifications
Table 98. Bayer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Bayer Recent Developments
Table 100. Emergent BioSolutions Corporation Information
Table 101. Emergent BioSolutions Description and Major Businesses
Table 102. Emergent BioSolutions Product Models, Descriptions and Specifications
Table 103. Emergent BioSolutions Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Emergent BioSolutions Recent Developments
Table 105. Walvax Corporation Information
Table 106. Walvax Description and Major Businesses
Table 107. Walvax Product Models, Descriptions and Specifications
Table 108. Walvax Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Walvax Recent Developments
Table 110. Chengdu Kanghua Biological Products Co., Ltd. Corporation Information
Table 111. Chengdu Kanghua Biological Products Co., Ltd. Description and Major Businesses
Table 112. Chengdu Kanghua Biological Products Co., Ltd. Product Models, Descriptions and Specifications
Table 113. Chengdu Kanghua Biological Products Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Chengdu Kanghua Biological Products Co., Ltd. Recent Developments
Table 115. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Corporation Information
Table 116. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Description and Major Businesses
Table 117. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 118. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Recent Developments
Table 120. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Corporation Information
Table 121. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Description and Major Businesses
Table 122. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 123. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Recent Developments
Table 125. Beijing Institute of Biological Products Co., Ltd. Corporation Information
Table 126. Beijing Institute of Biological Products Co., Ltd. Description and Major Businesses
Table 127. Beijing Institute of Biological Products Co., Ltd. Product Models, Descriptions and Specifications
Table 128. Beijing Institute of Biological Products Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Beijing Institute of Biological Products Co., Ltd. Recent Developments
Table 130. CanSino Biological Co., Ltd. Corporation Information
Table 131. CanSino Biological Co., Ltd. Description and Major Businesses
Table 132. CanSino Biological Co., Ltd. Product Models, Descriptions and Specifications
Table 133. CanSino Biological Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. CanSino Biological Co., Ltd. Recent Developments
Table 135. Hualan Biological Vaccine Co., Ltd. Corporation Information
Table 136. Hualan Biological Vaccine Co., Ltd. Description and Major Businesses
Table 137. Hualan Biological Vaccine Co., Ltd. Product Models, Descriptions and Specifications
Table 138. Hualan Biological Vaccine Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Hualan Biological Vaccine Co., Ltd. Recent Developments
Table 140. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Corporation Information
Table 141. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Description and Major Businesses
Table 142. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Product Models, Descriptions and Specifications
Table 143. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Recent Developments
Table 145. Key Raw Materials Distribution
Table 146. Raw Materials Key Suppliers
Table 147. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 148. Milestones in Production Technology Evolution
Table 149. Distributors List
Table 150. Market Trends and Market Evolution
Table 151. Market Drivers and Opportunities
Table 152. Market Challenges, Risks, and Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Bacterial Vaccines for Humans Product Picture
Figure 2. Global Bacterial Vaccines for Humans Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Meningococcal Vaccine Product Picture
Figure 4. Hib Vaccine Product Picture
Figure 5. BCG Vaccine Product Picture
Figure 6. Typhoid Vaccine Product Picture
Figure 7. Anthrax Vaccine Product Picture
Figure 8. Global Bacterial Vaccines for Humans Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Bacterial Vaccines for Humans Report Years Considered
Figure 13. Global Bacterial Vaccines for Humans Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 15. Global Bacterial Vaccines for Humans Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Bacterial Vaccines for Humans Revenue Market Share by Region (2020-2031)
Figure 17. Global Bacterial Vaccines for Humans Sales (2020-2031) & (K Units)
Figure 18. Global Bacterial Vaccines for Humans Sales (CAGR) by Region (2020-2031) (K Units)
Figure 19. Global Bacterial Vaccines for Humans Sales Market Share by Region (2020-2031)
Figure 20. Top 5 and Top 10 Manufacturers Bacterial Vaccines for Humans Sales Volume Market Share in 2024
Figure 21. Global Bacterial Vaccines for Humans Revenue Market Share Ranking (2024)
Figure 22. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 23. Meningococcal Vaccine Revenue Market Share by Manufacturer in 2024
Figure 24. Hib Vaccine Revenue Market Share by Manufacturer in 2024
Figure 25. BCG Vaccine Revenue Market Share by Manufacturer in 2024
Figure 26. Typhoid Vaccine Revenue Market Share by Manufacturer in 2024
Figure 27. Anthrax Vaccine Revenue Market Share by Manufacturer in 2024
Figure 28. Global Bacterial Vaccines for Humans Sales Market Share by Type (2020-2031)
Figure 29. Global Bacterial Vaccines for Humans Revenue Market Share by Type (2020-2031)
Figure 30. Global Bacterial Vaccines for Humans Sales Market Share by Application (2020-2031)
Figure 31. Global Bacterial Vaccines for Humans Revenue Market Share by Application (2020-2031)
Figure 32. North America Bacterial Vaccines for Humans Sales YoY (2020-2031) & (K Units)
Figure 33. North America Bacterial Vaccines for Humans Revenue YoY (2020-2031) & (US$ Million)
Figure 34. North America Top 5 Manufacturers Bacterial Vaccines for Humans Sales Revenue (US$ Million) in 2024
Figure 35. North America Bacterial Vaccines for Humans Sales Volume (K Units) by Type (2020- 2031)
Figure 36. North America Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 37. North America Bacterial Vaccines for Humans Sales Volume (K Units) by Application (2020-2031)
Figure 38. North America Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Application (2020-2031)
Figure 39. US Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 40. Canada Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 41. Mexico Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 42. Europe Bacterial Vaccines for Humans Sales YoY (2020-2031) & (K Units)
Figure 43. Europe Bacterial Vaccines for Humans Revenue YoY (2020-2031) & (US$ Million)
Figure 44. Europe Top 5 Manufacturers Bacterial Vaccines for Humans Sales Revenue (US$ Million) in 2024
Figure 45. Europe Bacterial Vaccines for Humans Sales Volume (K Units) by Type (2020-2031)
Figure 46. Europe Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Type (2020-2031)
Figure 47. Europe Bacterial Vaccines for Humans Sales Volume (K Units) by Application (2020-2031)
Figure 48. Europe Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Application (2020-2031)
Figure 49. Germany Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 50. France Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 51. U.K. Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 52. Italy Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 53. Russia Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 54. Asia-Pacific Bacterial Vaccines for Humans Sales YoY (2020-2031) & (K Units)
Figure 55. Asia-Pacific Bacterial Vaccines for Humans Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Top 8 Manufacturers Bacterial Vaccines for Humans Sales Revenue (US$ Million) in 2024
Figure 57. Asia-Pacific Bacterial Vaccines for Humans Sales Volume (K Units) by Type (2020- 2031)
Figure 58. Asia-Pacific Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 59. Asia-Pacific Bacterial Vaccines for Humans Sales Volume (K Units) by Application (2020-2031)
Figure 60. Asia-Pacific Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Application (2020-2031)
Figure 61. Indonesia Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 62. Japan Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 63. South Korea Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 64. China Taiwan Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 65. India Bacterial Vaccines for Humans Revenue (2020-2031) & (US$ Million)
Figure 66. Central and South America Bacterial Vaccines for Humans Sales YoY (2020-2031) & (K Units)
Figure 67. Central and South America Bacterial Vaccines for Humans Revenue YoY (2020-2031) & (US$ Million)
Figure 68. Central and South America Top 5 Manufacturers Bacterial Vaccines for Humans Sales Revenue (US$ Million) in 2024
Figure 69. Central and South America Bacterial Vaccines for Humans Sales Volume (K Units) by Type (2021-2031)
Figure 70. Central and South America Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Type (2020-2031)
Figure 71. Central and South America Bacterial Vaccines for Humans Sales Volume (K Units) by Application (2020-2031)
Figure 72. Central and South America Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Application (2020-2031)
Figure 73. Brazil Bacterial Vaccines for Humans Revenue (2020-2025) & (US$ Million)
Figure 74. Argentina Bacterial Vaccines for Humans Revenue (2020-2025) & (US$ Million)
Figure 75. Middle East, and Africa Bacterial Vaccines for Humans Sales YoY (2020-2031) & (K Units)
Figure 76. Middle East and Africa Bacterial Vaccines for Humans Revenue YoY (2020-2031) & (US$ Million)
Figure 77. Middle East and Africa Top 5 Manufacturers Bacterial Vaccines for Humans Sales Revenue (US$ Million) in 2024
Figure 78. Middle East and Africa Bacterial Vaccines for Humans Sales Volume (K Units) by Type (2021-2031)
Figure 79. South America Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Type (2020-2031)
Figure 80. Middle East and Africa Bacterial Vaccines for Humans Sales Volume (K Units) by Application (2020-2031)
Figure 81. Middle East and Africa Bacterial Vaccines for Humans Sales Revenue (US$ Million) by Application (2020-2031)
Figure 82. GCC Countries Bacterial Vaccines for Humans Revenue (2020-2025) & (US$ Million)
Figure 83. Turkey Bacterial Vaccines for Humans Revenue (2020-2025) & (US$ Million)
Figure 84. Egypt Bacterial Vaccines for Humans Revenue (2020-2025) & (US$ Million)
Figure 85. South Africa Bacterial Vaccines for Humans Revenue (2020-2025) & (US$ Million)
Figure 86. Bacterial Vaccines for Humans Industry Chain Mapping
Figure 87. Regional Bacterial Vaccines for Humans Manufacturing Base Distribution (%)
Figure 88. Global Bacterial Vaccines for Humans Production Market Share by Region (2020-2031)
Figure 89. Bacterial Vaccines for Humans Production Process
Figure 90. Regional Bacterial Vaccines for Humans Production Cost Structure
Figure 91. Channels of Distribution (Direct Vs Distribution)
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Wireless Split Keyboard Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Ergonomic Adjustable Computer Chair Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Trackless Keyboard Tray Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232